Delaware Judge Denies Cordis Motion In Patent Fight With Boston Scientific
This article was originally published in The Gray Sheet
Johnson & Johnson/Cordis plans to appeal a Delaware court's denial of its motion for new trials in two drug-eluting stent patent disputes with Boston Scientific
You may also be interested in...
FDA advisory panel members decided Dec. 7 that the benefit of drug-eluting stent use in FDA-approved indications outweighs the risks. But the panel expressed some skepticism about the strength of data measuring the long-term incidence of blood clots
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.